×

athenahealth, Inc. Reports Third Quarter Fiscal Year 2015 Results

Q3 2015 Financial Results

  • 24% Revenue Growth Over Third Quarter of 2014
  • Non-GAAP Adjusted Operating Income of $25.4 million
  • GAAP Net Income of $5.8 million, or $0.15 Per Diluted Share
  • Non-GAAP Adjusted Net Income of $14.3 million, or $0.36 Per Diluted Share

WATERTOWN, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) -- athenahealth, Inc. (NASDAQ:ATHN) (“athenahealth” or “we”), a leading provider of cloud-based services and mobile applications for medical groups and health systems, today announced financial and operational results for the third quarter of fiscal year 2015. We will conduct a conference call tomorrow, Friday, October 23, 2015, at 8:00 a.m. Eastern Time to discuss these results and management’s outlook for future financial and operational performance.

  • Total revenue for the three months ended September 30, 2015, was $236.1 million, compared to $190.4 million in the same period last year, an increase of 24%.
    • Revenue from athenahealth-branded services was $217.8 million, an increase of 24% over $175.6 million for the three months ended September 30, 2014.
  • Total revenue for the nine months ended September 30, 2015, was $667.2 million, compared to $539.4 million in the same period last year, an increase of 24%.
    • Revenue from athenahealth-branded services was $619.0 million, an increase of 25% over $494.1 million for the nine months ended September 30, 2014.
  • Grew net new active physicians on athenaCollector® (3,953 physicians added), athenaClinicals® (2,818 physicians added), and athenaCommunicator® (3,422 physicians added) for the three months ended September 30, 2015, compared to athenaCollector (3,420 physicians added), athenaClinicals (2,786 physicians added), and athenaCommunicator (3,846 physicians added) in the same period last year.


“Our unique results-oriented model and continuously expanding technology-enabled services are the foundation for our credibility and continued growth in health care. Our allegiance to drive both clinical and financial outcomes for our clients is fundamentally what differentiates us from traditional software vendors,” said Jonathan Bush, chairman and chief executive officer of athenahealth. “While we are still in the early days of bringing the full power of the internet to health care, we are gaining nice momentum as we innovate to improve the way patients are managed and advance connectedness across our network and the care continuum at large. This quarter again reflects progress being made. There is no precedent set for what we are doing to advance health care.”

  • For the three months ended September 30, 2015, Non-GAAP Adjusted Gross Margin was 62.9%, compared to 61.2% in the same period last year.
  • For the three months ended September 30, 2015, Non-GAAP Adjusted Operating Income was $25.4 million, or 10.8% of total revenue, compared to $18.5 million, or 9.7% of total revenue, in the same period last year.
  • For the three months ended September 30, 2015, GAAP net income was $5.8 million, or $0.15 per diluted share, compared to GAAP net loss of $1.6 million, or $0.04 per diluted share, in the same period last year.
  • For the three months ended September 30, 2015, Non-GAAP Adjusted Net Income was $14.3 million, or $0.36 per diluted share, compared to $10.4 million, or $0.27 per diluted share, in the same period last year.


“We are headed into the home stretch of 2015 and feel good about this year’s accomplishments and the investments made to drive forward progress,” said Kristi Matus, chief financial and administrative officer of athenahealth. “Through innovation, we continue to introduce new efficiencies for the health care industry and drive ongoing profitable growth for athenahealth. This quarter alone, we added a record 4,784 providers to our network, grew consolidated revenue by 24%, and delivered a Non-GAAP Adjusted Gross Margin of 62.9%. We are headed into the fourth quarter on track to deliver against many of our 2015 financial and operational goals.”

Our fiscal year 2015 guidance we released in conjunction with our fourth quarter and full year 2014 earnings call on February 6, 2015, is summarized in the following table:

For the Fiscal Year Ending December 31, 2015
Forward-Looking Guidance
GAAP Total Revenue$905 - $925 million
Non-GAAP Adjusted Gross Margin62.5% - 63.5%
Non-GAAP Adjusted Operating Income$75 - $85 million
Non-GAAP Adjusted Net Income per Diluted Share$1.10 - $1.20
Non-GAAP Tax Rate 40 %


We are not making any changes to the fiscal year 2015 guidance we released in conjunction with our fourth quarter and full year 2014 earnings call on February 6, 2015. However, based on our year-to-date performance and our current expectations for Q4 2015, we are providing additional insight into our fiscal year 2015 guidance as follows:

  • We expect GAAP Total Revenue to be at or above the mid-point of the $905 million to $925 million guidance range.
  • We expect Non-GAAP Adjusted Gross Margin to be close to the high end of the 62.5% to 63.5% guidance range.
  • We expect Non-GAAP Adjusted Operating Income to be above the high end of the $75 million to $85 million guidance range.
  • Finally, we expect Non-GAAP Adjusted Net Income per Diluted Share to be above the high end of the $1.10 to $1.20 guidance range.


Please refer to our press release dated February 5, 2015 for a reconciliation of these non-GAAP financial measures to comparable GAAP measures for fiscal year 2015 guidance.

Our 8th Annual Investor Summit will be held at our Watertown, Massachusetts headquarters on Thursday, December 10, 2015. Please note that, due to limited capacity, attendance at the Investor Summit is by invitation only. However, similar to prior years, a live webcast of this event can be accessed via the Investors section of athenahealth’s website at www.athenahealth.com.

Use of Non-GAAP Financial Measures

In our earnings releases, prepared remarks, conference calls, slide presentations, and webcasts, we may use or discuss non-GAAP financial measures, as defined by Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investors section of our website at www.athenahealth.com.

Conference Call Information

To participate in our live conference call and webcast, please dial 877-853-5645 (or 408-940-3868 for international calls) using conference code no. 50137013, or visit the Investors section of our website at www.athenahealth.com. A replay will be available for one week following the conference call at 855-859-2056 (and 404-537-3406 for international calls) using conference code no. 50137013. A webcast replay will also be archived on our website.

About athenahealth, Inc.

athenahealth is a leading provider of cloud-based services for electronic health records (EHR), revenue cycle management and medical billing, patient engagement, care coordination, and population health management, as well as Epocrates and other point-of-care mobile apps. We connect care and drive meaningful, measurable results for more than 72,000 health care providers in medical practices and health systems nationwide. For more information, please visit www.athenahealth.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements reflecting management’s expectations for future financial and operational performance and operating expenditures, expected growth, and business outlook, including the fiscal year 2015 guidance and additional insight thereto; statements regarding the benefits of our service offerings and differentiation of our business model from traditional software vendors; statements regarding the expansion of our network, including physician and provider additions to our network; statements regarding creation of the health care Internet and connected care; statements regarding our market opportunity; statements regarding the expected value creation from our investments; and statements found under our “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” section of this release. The forward-looking statements in this release do not constitute guarantees of future performance. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: our fluctuating operating results; our variable sales and implementation cycles, which may result in fluctuations in our quarterly results; risks associated with the acquisition and integration of companies and new technologies to achieve expected synergies; risks associated with our expectations regarding our ability to maintain profitability; the impact of increased sales and marketing and research and development expenditures, including whether increased expansion in revenues is attained and impacts on margins and profitability; changes in tax rates or exposure to additional tax liabilities; the highly competitive industry in which we operate and the relative immaturity of the market for our service offerings; and the evolving and complex governmental and regulatory compliance environment in which we and our clients operate. Forward-looking statements may often be identified with words such as “we expect,” “we anticipate,” “upcoming,” “aim,” or similar indications of future expectations. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise. For additional disclosure regarding these and other risks faced by us, please see the disclosures contained in our public filings with the Securities and Exchange Commission (“SEC”), available on the Investors section of our website at www.athenahealth.com and on the SEC’s website at www.sec.gov.

athenahealth, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands, except per share amounts)
September 30,December 31,
2015 2014
Assets
Current assets:
Cash and cash equivalents $ 116,712 $ 73,787
Marketable securities 40,950
Accounts receivable, net 144,781 121,710
Deferred tax asset, net 12,504
Prepaid expenses and other current assets 32,892 22,627
Total current assets 306,889 259,074
Property and equipment, net 309,072 271,552
Capitalized software costs, net 102,127 56,574
Purchased intangible assets, net 131,995 139,422
Goodwill 229,157 198,049
Investments and other assets 12,162 7,327
Total assets $ 1,091,402 $ 931,998
Liabilities & Stockholders’ Equity
Current liabilities:
Accounts payable $ 14,219 $ 9,410
Accrued compensation 75,732 71,768
Accrued expenses 45,652 37,033
Line of credit 35,000
Long-term debt 7,500 15,000
Deferred revenue 35,807 28,949
Deferred tax liability, net 8,449
Total current liabilities 178,910 205,609
Deferred rent, net of current portion 26,969 19,412
Long-term debt, net of current portion 292,500 158,750
Deferred revenue, net of current portion 55,566 54,473
Long-term deferred tax liability, net 17,631 10,417
Other long-term liabilities 7,676 8,214
Total liabilities 579,252 456,875
Stockholders’ equity:
Preferred stock, $0.01 par value: 5,000 shares authorized; no shares issued and outstanding at September 30, 2015 and December 31, 2014
Common stock, $0.01 par value: 125,000 shares authorized; 40,089 shares issued and 38,811 shares outstanding at September 30, 2015; 39,402 shares issued and 38,124 shares outstanding at December 31, 2014 401 395
Additional paid-in capital 499,321 443,259
Treasury stock, at cost, 1,278 shares (1,200) (1,200)
Accumulated other comprehensive (loss) income (1,165) 24,188
Retained earnings 14,793 8,481
Total stockholders’ equity 512,150 475,123
Total liabilities and stockholders’ equity $ 1,091,402 $ 931,998
athenahealth, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited, in thousands, except per share amounts)
Three Months EndedNine Months Ended
September 30,September 30,
2015 2014 2015 2014
Revenue:
Business services$ 224,990 $ 179,711 $ 638,156 $ 510,162
Implementation and other 11,078 10,717 29,040 29,223
Total revenue 236,068 190,428 667,196 539,385
Expense:
Direct operating 94,850 79,343 269,306 226,265
Selling and marketing 55,927 45,206 163,705 139,155
Research and development 22,560 18,087 70,675 49,659
General and administrative 34,778 31,800 107,093 91,600
Depreciation and amortization 24,763 17,258 67,216 46,693
Total expense 232,878 191,694 677,995 553,372
Operating income (loss) 3,190 (1,266) (10,799) (13,987)
Other income (expense):
Interest expense (1,620) (1,244) (4,192) (3,784)
Other income (expense) 7,590 26 28,715 (151)
Total other income (expense) 5,970 (1,218) 24,523 (3,935)
Income (loss) before income tax (provision) benefit 9,160 (2,484) 13,724 (17,922)
Income tax (provision) benefit (3,365) 853 (7,412) 6,074
Net income (loss)$ 5,795 $ (1,631)$ 6,312 $ (11,848)
Net income (loss) per share – Basic$ 0.15 $ (0.04)$ 0.16 $ (0.31)
Net income (loss) per share – Diluted$ 0.15 $ (0.04)$ 0.16 $ (0.31)
Weighted average shares used in computing net income (loss) per share:
Basic 38,714 37,999 38,523 37,783
Diluted 39,536 37,999 39,476 37,783
athenahealth, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
Nine Months Ended September 30,
2015 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 6,312 $ (11,848)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization 85,869 69,416
Excess tax benefit from stock-based awards (8,367)
Deferred income tax (1,652) (6,494)
Stock-based compensation expense 47,943 38,986
Gain on sale of marketable securities (28,656)
Other reconciling adjustments 6 121
Changes in operating assets and liabilities:
Accounts receivable, net (21,941) (14,164)
Prepaid expenses and other current assets (1,296) (6,352)
Other long-term assets (2,090) 18
Accounts payable 5,611 5,070
Accrued expenses and other long-term liabilities 4,232 8,387
Accrued compensation 4,085 10,379
Deferred revenue 6,015 1,830
Deferred rent 6,848 8,792
Net cash provided by operating activities 102,919 104,141
CASH FLOWS FROM INVESTING ACTIVITIES:
Capitalized software development costs (77,714) (41,232)
Purchases of property and equipment (65,090) (51,131)
Payments on acquisitions, net of cash acquired (39,890)
Proceeds from sales of marketable securities 29,756
Change in restricted cash 2,955
Other investing activities (2,610) (250)
Net cash used in investing activities (155,548) (89,658)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under stock plans and warrants 18,046 19,723
Taxes paid related to net share settlement of stock awards (20,664) (28,302)
Excess tax benefit from stock-based awards 8,367
Proceeds from line of credit 60,000
Payments on line of credit (95,000)
Proceeds from long-term debt 300,000
Payments on long-term debt (173,750) (11,250)
Debt issuance costs (987)
Net cash provided by (used in) financing activities 96,012 (19,829)
Effect of exchange rate changes on cash and cash equivalents (458) (126)
Net increase (decrease) in cash and cash equivalents 42,925 (5,472)
Cash and cash equivalents at beginning of period 73,787 65,002
Cash and cash equivalents at end of period $ 116,712 $ 59,530
athenahealth, Inc.
STOCK-BASED COMPENSATION
(Unaudited, in thousands)
Set forth below is a breakout of stock-based compensation impacting the Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2015, and 2014:
Three Months EndedNine Months Ended
September 30,September 30,
2015 2014 2015 2014
Stock-based compensation charged to Condensed Consolidated Statements of Income:
Direct operating$ 3,584 $ 2,987 $ 10,883 $ 8,806
Selling and marketing 4,162 3,652 13,745 10,878
Research and development 2,164 1,499 6,707 5,298
General and administrative 5,070 4,283 16,608 14,004
Total stock-based compensation expense 14,980 12,421 47,943 38,986
Amortization of capitalized stock-based compensation related to software development (1) 1,244 635 3,013 1,515
Total$ 16,224 $ 13,056 $ 50,956 $ 40,501
(1) In addition, for the three months ended September 30, 2015, and 2014, $1.8 million and $1.7 million, respectively, of stock-based compensation was capitalized in the line item Capitalized software costs, net in the Condensed Consolidated Balance Sheets for which $1.2 million and $0.6 million, respectively, of amortization was included in the line item Depreciation and amortization in the Condensed Consolidated Statements of Income. For the nine months ended September 30, 2015, and 2014, $5.4 million and $3.5 million, respectively, of stock-based compensation was capitalized in the line item Capitalized software costs, net in the Condensed Consolidated Balance Sheets for which $3.0 million and $1.5 million, respectively, of amortization was included in the line item Depreciation and amortization in the Condensed Consolidated Statements of Income.
athenahealth, Inc.
AMORTIZATION OF PURCHASED INTANGIBLE ASSETS
(Unaudited, in thousands)
Set forth below is a breakout of amortization of purchased intangible assets impacting the Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2015, and 2014:
Three Months EndedNine Months Ended
September 30,September 30,
Amortization of purchased intangible assets allocated to: 2015 2014 2015 2014
Direct operating$ 3,662 $ 2,534 $ 11,177 $ 9,189
Selling and marketing 2,373 4,206 7,119 13,178
Total amortization of purchased intangible assets$ 6,035 $ 6,740 $ 18,296 $ 22,367
athenahealth, Inc.
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
TO COMPARABLE GAAP MEASURES
(Unaudited, in thousands, except per share amounts)
The following is a reconciliation of the non-GAAP financial measures used by us to describe our financial results determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”). An explanation of these measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”
While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of our business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP.
Please note that these figures may not sum exactly due to rounding.
Non-GAAP Adjusted Gross Margin
Set forth below is a presentation of our “Non-GAAP Adjusted Gross Profit” and “Non-GAAP Adjusted Gross Margin,” which represents Non-GAAP Adjusted Gross Profit as a percentage of total revenue.
(unaudited, in thousands)Three Months EndedNine Months Ended
September 30,September 30,
2015 2014 2015 2014
Total revenue$ 236,068 $ 190,428 $ 667,196 $ 539,385
Direct operating expense 94,850 79,343 269,306 226,265
Total revenue less direct operating expense 141,218 111,085 397,890 313,120
Add: Stock-based compensation 3,584 2,987 10,883 8,806
allocated to direct operating expense
Add: Amortization of purchased intangible assets 3,662 2,534 11,177 9,189
allocated to direct operating expense
Non-GAAP Adjusted Gross Profit$ 148,464 $ 116,606 $ 419,950 $ 331,115
Non-GAAP Adjusted Gross Margin 62.9% 61.2% 62.9% 61.4%
Non-GAAP Adjusted EBITDA
Set forth below is a reconciliation of our “Non-GAAP Adjusted EBITDA” and “Non-GAAP Adjusted EBITDA Margin,” which represents Non-GAAP Adjusted EBITDA as a percentage of total revenue.
(unaudited, in thousands)Three Months EndedNine Months Ended
September 30,September 30,
2015 2014 2015 2014
Total revenue$ 236,068 $ 190,428 $ 667,196 $ 539,385
GAAP net income (loss) 5,795 (1,631) 6,312 (11,848)
Add: Provision for (benefit) from income taxes 3,365 (853) 7,412 (6,074)
Add: Total other (income) expense (5,970) 1,218 (24,523) 3,935
Add: Stock-based compensation expense 14,980 12,421 47,943 38,986
Add: Depreciation and amortization 24,763 17,258 67,216 46,693
Add: Amortization of purchased intangible assets 6,035 6,740 18,296 22,367
Add: Integration and transaction costs 964
Add: Lease termination costs 4,446
Non-GAAP Adjusted EBITDA$ 48,968 $ 35,153 $ 128,066 $ 94,059
Non-GAAP Adjusted EBITDA Margin 20.7% 18.5% 19.2% 17.4%
Non-GAAP Adjusted Operating Income
Set forth below is a reconciliation of our “Non-GAAP Adjusted Operating Income” and “Non-GAAP Adjusted Operating Income Margin,” which represents Non-GAAP Adjusted Operating Income as a percentage of total revenue.
(unaudited, in thousands)Three Months EndedNine Months Ended
September 30,September 30,
2015 2014 2015 2014
Total revenue$ 236,068 $ 190,428 $ 667,196 $ 539,385
GAAP net income (loss) 5,795 (1,631) 6,312 (11,848)
Add: Provision for (benefit) from income taxes 3,365 (853) 7,412 (6,074)
Add: Total other (income) expense (5,970) 1,218 (24,523) 3,935
Add: Stock-based compensation expense 14,980 12,421 47,943 38,986
Add: Amortization of capitalized stock-based compensation related to software development 1,244 635 3,013 1,515
Add: Amortization of purchased intangible assets 6,035 6,740 18,296 22,367
Add: Integration and transaction costs 964
Add: Lease termination costs 4,446
Non-GAAP Adjusted Operating Income$ 25,449 $ 18,530 $ 63,863 $ 48,881
Non-GAAP Adjusted Operating Income Margin 10.8% 9.7% 9.6% 9.1%
Non-GAAP Adjusted Net Income
Set forth below is a reconciliation of our “Non-GAAP Adjusted Net Income” and “Non-GAAP Adjusted Net Income per Diluted Share.”
(unaudited, in thousands)Three Months EndedNine Months Ended
September 30,September 30,
2015 2014 2015 2014
GAAP net income (loss)$ 5,795 $ (1,631)$ 6,312 $ (11,848)
Add: Stock-based compensation expense 14,980 12,421 47,943 38,986
Add: Amortization of capitalized stock-based compensation related to software development 1,244 635 3,013 1,515
Add: Amortization of purchased intangible assets 6,035 6,740 18,296 22,367
Add: Integration and transaction costs 964
Add: Lease termination costs 4,446
Less: Gain on sale of marketable securities (7,585) (28,656)
Sub-total of tax deductible items 14,674 19,796 46,006 62,868
Less: Tax impact of tax deductible items (1) (5,870) (7,918) (18,402) (25,147)
Add: Tax impact resulting from applying non-GAAP tax rate (2) (299) 140 1,922 1,095
Non-GAAP Adjusted Net Income$ 14,300 $ 10,387 $ 35,838 $ 26,968
Weighted average shares - diluted 39,536 37,999 39,476 37,783
Non-GAAP Adjusted Net Income per Diluted Share$ 0.36 $ 0.27 $ 0.91 $ 0.71
(1) Tax impact calculated using a statutory tax rate of 40%.
(2)Represents adjusting the GAAP net loss at a non-GAAP tax rate of 40%. We used a non-GAAP tax rate of 40% to normalize the tax impact to our Non-GAAP Adjusted Net Income per Diluted Share based on the fact that a relatively small change in pre-tax GAAP income (loss) in any one period could result in a volatile GAAP effective tax rate.
(unaudited, in thousands)Three Months EndedNine Months Ended
September 30,September 30,
2015 2014 2015 2014
GAAP net income (loss) per share - diluted$ 0.15 $ (0.04)$ 0.16 $ (0.31)
Add: Stock-based compensation expense 0.38 0.33 1.21 1.03
Add: Amortization of capitalized stock-based compensation related to software development 0.03 0.02 0.08 0.04
Add: Amortization of purchased intangible assets 0.15 0.18 0.46 0.59
Add: Integration and transaction costs 0.02
Add: Lease termination costs 0.11
Less: Gain on sale of marketable securities (0.19) (0.73)
Sub-total of tax deductible items 0.37 0.52 1.17 1.66
Less: Tax impact of tax deductible items (1) (0.15) (0.21) (0.47) (0.67)
Add: Tax impact resulting from applying non-GAAP tax rate (2) (0.01) 0.05 0.03
Non-GAAP Adjusted Net Income per Diluted Share$ 0.36 $ 0.27 $ 0.91 $ 0.71
Weighted average shares - diluted 39,536 37,999 39,476 37,783
(1) Tax impact calculated using a statutory tax rate of 40%.
(2) Represents adjusting the GAAP net loss at a non-GAAP tax rate of 40%. We used a non-GAAP tax rate of 40% to normalize the tax impact to our Non-GAAP Adjusted Net Income per Diluted Share based on the fact that a relatively small change in pre-tax GAAP income (loss) in any one period could result in a volatile GAAP effective tax rate.


Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of athenahealth and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

Management defines “Non-GAAP Adjusted Gross Profit” as total revenue, less direct operating expense, plus (1) stock-based compensation expense allocated to direct operating expense and (2) amortization of purchased intangible assets allocated to direct operating expense, and “Non-GAAP Adjusted Gross Margin” as Non-GAAP Adjusted Gross Profit as a percentage of total revenue. Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends. Moreover, management believes that these measures enable investors and financial analysts to closely monitor and understand changes in our ability to generate income from ongoing business operations.

Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP net income (loss) before provision for (benefit) from income taxes, total other (income) expense, stock-based compensation expense, depreciation and amortization, amortization of purchased intangible assets, integration and transaction costs, and lease termination costs and “Non-GAAP Adjusted EBITDA Margin” as Non-GAAP Adjusted EBITDA as a percentage of total revenue. Management defines “Non-GAAP Adjusted Operating Income” as the sum of GAAP net income (loss) before provision for (benefit) from income taxes, total other (income) expense, stock-based compensation expense, amortization of capitalized stock-based compensation related to software development, amortization of purchased intangible assets, integration and transaction costs, and lease termination costs and “Non-GAAP Adjusted Operating Income Margin” as Non-GAAP Adjusted Operating Income as a percentage of total revenue. Management defines “Non-GAAP Adjusted Net Income” as the sum of GAAP net income (loss) before stock-based compensation expense, amortization of capitalized stock-based compensation related to software development, amortization of purchased intangible assets, integration and transaction costs, lease termination costs, and gain on sale of marketable securities and any tax impact related to these preceding items, and an adjustment to the tax provision for the non-GAAP tax rate and “Non-GAAP Adjusted Net Income per Diluted Share” as Non-GAAP Adjusted Net Income divided by weighted average diluted shares outstanding. Management considers all of these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance.

Management excludes or adjusts each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

  • Stock-based compensation expense and amortization of capitalized stock-based compensation related to software development — excluded because these are non-cash expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred.
  • Amortization of purchased intangible assets — purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
  • Integration and transaction costs — Integration costs are the severance payments and retention bonuses for certain employees relating to the Razor Insights, LLC acquisition. Transaction costs are non-recurring costs related to specific transactions. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
  • Lease termination costs — represents costs to terminate certain lease agreements. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are incurred.
  • Gain on sale of marketable securities — represents gain on sale of marketable securities. Management does not believe such gains accurately reflect the performance of our ongoing operations for the period in which such gains are reported.
  • Non-GAAP tax rate — We use a non-GAAP tax rate of 40% to normalize the tax impact to our Non-GAAP Adjusted Net Income per Diluted Share based on the fact that a relatively small change in pre-tax GAAP income (loss) in any one period could result in a volatile GAAP effective tax rate.


Contact Info: Dana Quattrochi athenahealth, Inc. (Investors) investorrelations@athenahealth.com (617) 402-1329 Holly Spring athenahealth, Inc. (Media) media@athenahealth.com (617) 402-1631

Source: athenahealth, Inc.